These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 23014187)

  • 1. Current treatment of acute myeloid leukemia.
    Roboz GJ
    Curr Opin Oncol; 2012 Nov; 24(6):711-9. PubMed ID: 23014187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
    Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M
    Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia.
    Rubnitz JE; Gibson B; Smith FO
    Pediatr Clin North Am; 2008 Feb; 55(1):21-51, ix. PubMed ID: 18242314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
    Ferrara F
    Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current therapeutic strategies in the management of acute myeloid leukemia].
    Fiegl M; Hiddemann W; Braess J
    Med Klin (Munich); 2007 Apr; 102(4):309-16. PubMed ID: 17426934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
    Miyawaki S
    Rinsho Ketsueki; 2014 Jan; 55(1):31-41. PubMed ID: 24492035
    [No Abstract]   [Full Text] [Related]  

  • 9. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
    Valcárcel D; Montesinos P; Sánchez-Ortega I; Brunet S; Esteve J; Martínez-Cuadrón D; Ribera JM; Tormo M; Bueno J; Duarte R; Llorente A; Torres JP; Guardia R; Sanz MA; Sierra AJ;
    Cancer; 2012 Jan; 118(2):410-7. PubMed ID: 21717435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
    Griffin PT; Komrokji RS; De Castro CM; Rizzieri DA; Melchert M; List AF; Lancet JE
    Am J Hematol; 2015 Sep; 90(9):796-9. PubMed ID: 26089240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1?
    Wolach O; Stone RM
    Curr Opin Hematol; 2015 Mar; 22(2):123-31. PubMed ID: 25594168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the management of acute myeloid leukemia in older adult patients.
    Rogers BB
    Oncol Nurs Forum; 2010 May; 37(3):E168-79. PubMed ID: 20439202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
    Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
    Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].
    Kurahashi S; Iwasaki T; Suzuki H; Sawamoto A; Sugimoto T; Narimatsu H; Adachi T; Hayakawa F; Sugiura I
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1617-21. PubMed ID: 17940376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions.
    Rosenblat TL; Jurcic JG
    Hematol Oncol Clin North Am; 2011 Dec; 25(6):1189-213. PubMed ID: 22093583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T; Yasuyama M; Kawauchi K
    Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
    Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
    Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.